倍他米松磷酸钠注射液治疗早产有效性和安全性研究进展

Research progress on the efficacy and safety of betamethasone sodium phosphate injection in the treatment of premature birth

倍他米松是地塞米松的同分异构体,具有抗炎、抗过敏、抗内毒素和免疫抑制等功能。倍他米松磷酸钠(BSP)注射液是倍他米松的磷酸盐制剂,作为一种糖皮质激素(ACS)类药物,其临床应用较广。BSP治疗早产已有充分的证据并被纳入各国指南,然而这些证据主要集中在高收入国家,中低收入国家相关证据则较少。我国关于BSP在产科应用疗效和安全性临床研究方面存在不足。关于倍他米松和地塞米松疗效和安全性直接比较的临床研究较少,BSP治疗早产后儿童期和成年期随访研究尚不足。因此,需进一步开展相关研究,为早产临床科学合理用药提供决策依据。

Betamethasone is an isomer of dexamethasone,which has anti-inflammatory,anti-allergic,antiendotoxin and immunosuppressive functions.Betamethasone sodium phosphate(BSP)injection is a phosphate preparation of betamethasone,which is widely used as a antenatal corticostemids(ACS)drug in clinical practice.There is sufficient evidence for the treatment of premature birth with BSP,and BSP has been included in national guidelines.However,the evidence related to its treatment of premature birth is mainly in high-income countries,and there is less evidence in low to middle-income countries.There is insufficient clinical research on the efficacy and safety of BSP in obstetric applications in China.There are few clinical studies on the direct comparison of efficacy and safety between betamethasone and dexamethasone,and the follow-up study of BSP in treating premature in childhood and adulthood is still insufficient.Further research is needed to provide a decision-making basis for the scientific and rational use of me dication in preterm birth.